SRRK · CIK 0001727196 · FY2025 live · 2025-12-31
Scholar Rock Holding Corp
View as
Model
Classic Z
FY2025
−5.74
Zone
Distress
Prior
—
Market DD
—
1y PD
—
Meridian Rank
15.82
0–100 · Classic Z tape · not a PD
Book standing
15
Year change
—
Market PD
—
O-score
18
Events on this name
Same published rows as Today. Not a live recompute.
Market PD unavailable
watch · 41
−5.74
Z″ −9.91
Score −5.74 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.821.2 × = 0.98X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−3.221.4 × = −4.50X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.953.3 × = −3.14X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
1.550.6 × = 0.93X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Scholar Rock Holding Corp is on classic Z at −5.74 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print; EBIT / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 26th percentile in Healthcare.
- NVCTDistressNuvectis Pharma, Inc.−5.74
- MISTDistressMilestone Pharmaceuticals Inc.−5.73
- FBIODistressFortress Biotech, Inc.−5.72
- REVBDistressREVELATION BIOSCIENCES, INC.−5.69
- TVRDDistressTvardi Therapeutics, Inc.−5.68
- EQDistressEquillium, Inc.−5.67
- IDXGDistressINTERPACE BIOSCIENCES, INC.−5.84
- LCTXDistressLineage Cell Therapeutics, Inc.−5.86
KPI widgets
Current assets
$385M
Total assets
$404M
Current liabilities
$55M
Total liabilities
$159M
Working capital
$330M
Retained earnings
−$1.3B
EBIT
−$385M
Total sales
$0
Book equity
$245M
Accession 0001104659-26-022551. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 13 Sept 2026.